Injecting Insight: Analyzing GLP-1 Agonist Use and Opportunities for Optimal Management Within an Integrated Health System Specialty Pharmacy According to the CDC, approximately 38 million Americans have diabetes and approximately…
STOUGHTON, Mass. (May 13, 2025)–Shields Health Solutions (Shields), the premier specialty pharmacy accelerator in the country announced it has partnered with Duke Health, a leading academic health system in North…
Patient Experience and Patient Outcomes: A Comprehensive Guide
According to the CDC, approximately 38 million Americans have diabetes (about 1 in 10) and approximately 90-95% of those have type 2 diabetes. GLP-1 and GLP-1/GIP agonists are now recognized…
Specialty Pharmacy Patient Experience and Patient Outcomes: A Comprehensive Guide Shields Health Solutions 11 min read Table of contents Contact Us Overview: Patient experience and patient outcomes, while two unique…
Whether through social media, traditional news outlets, or word of mouth, discussions about GLP-1 therapy are everywhere. These medications, originally approved by the FDA for the treatment of Type 2…
Every year, more than 8,000 professionals and over 1,400 companies attend the leading specialty pharmacy conference in the nation, Asembia Summit 2024 marked its 20th anniversary — and we couldn’t be…
This poster evaluates the clinical and quality outcomes of a bleeding disorder program at a health system HSSP.